CRISPR news roundup

perv free piglets eGenesisIt’s mid-August, but CRISPR never goes on vacation. Not to be missed this week is the Science paper by George Church’s team. They have cloned 15 PERV-free piglets, meaning porcine retrovirus sequences have been edited out. The animals can now “serve as a foundation pig strain, which can be further engineered to provide safe and effective organ and tissue resources for xenotransplantation,” researchers write. According to the Harvard geneticist, the first pig-to-human transplants could occur within two years. Another article in the same journal feels the pulse of public perception of human genome editing, concluding that opinions are nuanced and the challenge is to find the best way to engage people in discussions about genome-editing regulation.

Edited embryos. Why to say yes or no

embryo-mainThe exploit announced last week by Nature marks an advancement in CRISPR performance in human embryos big enough to say that yes, germ line editing will probably become a viable option sooner or later. It means that some genetic diseases (at least those caused by a single mutation) can be corrected not only in the treated individuals but also in their offspring. The idea of genetic diseases disappearing from the face of Earth is bound to remain a dream, as Eric Lander explained at the 2015 Washington Summit on Human Gene Editing. In short, with rare Mendelian diseases, the vast majority of situations can currently be addressed by in vitro fertilization and preimplantation genetic diagnosis, while complex diseases are, well, too complex to handle. Anyway, when you come to efficiency and accuracy, results achieved by Shoukhrat Mitalipov and colleagues are exciting: CRISPR science walks on robust and fast legs. As for the bioethics of the experiment, we should try not to get stuck with overused labels. Continue reading

Anti-terror training for CRISPR


Safe genes” is what it’s called, and it’s a program for the responsible development of gene editing technologies funded with $65 million by the US Defense Advanced Research Projects Agency (Darpa). The grant will go to seven teams including top scientists such as CRISPR co-inventor Jennifer Doudna and synthetic biologist George Church. Finding reversible ways to control gene editing is a national security issue, in the event CRISPR falls into the wrong hands. But Darpa intends also to foster peaceful applications, by encouraging innovation and mitigating risks which might accidentally arise in civilian labs. Think of new CRISPR variants that can distinguish between highly similar genetic sequences, or molecular mechanisms to finely modulate the technology of gene drives, which is experimented to propagate modifications through entire populations.  Continue reading

Toward a pool for CRISPR patents. Will it work?

patent pool lampadine colorate

Berkeley vs. Boston. Jennifer Doudna vs. Feng Zhang. The patent battle on the technique that is revolutionizing life sciences has often been described as a duel between the group that first experimented the CRISPR platform on the genome of bacteria and the group that, a few months later, adapted the system for use in eukaryotic cells. But the patent landscape is more complicated than that, and there are worries that the stunning potential of this genetic modification technology may crumble under a mountain of intellectual property rights claims. The good news is that several patent holders are discussing how to merge their assets into a joint licensing pool, to allow interested researchers to deal with a single subject. But will this strategy be suffice to safeguard the common interest, which is to enable as many groups as possible to work to turn CRISPR promises into reality? Continue reading

An intelligence team for CRISPR warrior proteins

doudna_crispr_wide-cb9478286d39615ed64291ea95d4cfe022596aa2-s900-c85The University of Berkeley has opened a glimpse into the way bacteria use CRISPR, the microbial immune system that inspired the invention of the method for genetic modification also known as CRISPR. The paper published in Science by Jennifer Doudna’s team is a fascinating piece of basic research and scientists are hopeful they will be able to turn the discovery into a new biotech tool. Continue reading

Run, CRISPR, run

A few artists are already interested in using CRISPR to explore the border between biology and art, but scientists have so far been able to develop the artistic potential of genetics more elegantly and surprisingly. In this Nature paper, George Church’s group recalls the beginnings of cinematography by introducing old images of a galloping horse into a dividing bacterial population. Harvard researchers have chosen a historical sequence captured by British photographer Eadweard Muybridge in 1887, using a code based on nucleotide triplets to specify pixels tonalities. The exploit is technically astonishing, and it is not just a divertissement. It represents a proof of concept that one day perhaps we will be able to build cellular recorders, that can collect and store what is going on inside cells. But enthusiasm for futuristic research applications is joined here by an ancient sense of wonder. That galloping horse turns upside down proportion and hierarchy: it is the great in the small, the elegant in the primitive, the mammal in bacteria. Science has become magic. Art indeed.


Clearing CRISPR of off-target suspicion

mathcrisprFaster, better, cheaper is a motto adopted by Nasa that perfectly fits CRISPR as well. The most popular technique for genetic modification, in fact, has the reputation of being quick, affordable and precise. This deserved good name was unexpectedly tarnished by a study questioning the technology precision, published in the June issue of Nature Methods. However, reports about CRISPR’s demise have been greatly exaggerated, to paraphrase Mark Twain. Just over a month later, three analyses challenging the controversial study are already available in the pre-publication archive bioRxiv, and Nature Methods has alerted its readers about the criticisms received by publishing an editorial note which could turn into a retraction. Continue reading